PriceTargets.com logo

Livongo Health - LVGO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$139.77 As of 10/30/2020 01:00 AM ET
+0 (0.00%)
Get New Livongo Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LVGO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LVGO

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Livongo Health in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $139.77.

This chart shows the closing price for LVGO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Livongo Health. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/29/2020KeyCorpBoost TargetOverweight$153.00 ➝ $156.00
10/29/2020Needham & Company LLCReiterated RatingHold
10/28/2020Piper SandlerDowngradeOverweight ➝ Neutral$55.00 ➝ $143.00
10/14/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$88.00 ➝ $150.00
8/24/2020Stifel NicolausDowngradeBuy ➝ Hold$137.00
8/11/2020CitigroupBoost TargetBuy$125.00 ➝ $170.00
8/7/2020BenchmarkDowngradeBuy ➝ Hold
8/6/2020Needham & Company LLCDowngradeBuy ➝ Hold
7/14/2020Credit Suisse GroupInitiated CoverageOutperform$132.00
7/14/2020CitigroupInitiated CoverageBuy$125.00
7/8/2020Needham & Company LLCBoost TargetBuy$70.00 ➝ $120.00
7/8/2020Royal Bank of CanadaBoost TargetOutperform$53.00 ➝ $120.00
7/7/2020KeyCorpBoost Target$85.00 ➝ $105.00
7/7/2020Morgan StanleyBoost TargetOverweight$62.00 ➝ $89.00
7/6/2020StephensInitiated CoverageOverweight$95.00
7/2/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$48.00 ➝ $70.00
6/25/2020CowenBoost TargetOutperform$69.00 ➝ $88.00
6/22/2020KeyCorpBoost TargetOverweight$52.00 ➝ $85.00
6/12/2020Leerink PartnersBoost TargetOutperform$55.00 ➝ $65.00
6/5/2020CowenInitiated CoverageOutperform$69.00
5/22/2020JPMorgan Chase & Co.Boost TargetOverweight$36.00 ➝ $63.00
5/21/2020Needham & Company LLCBoost TargetBuy$55.00 ➝ $70.00
5/7/2020Morgan StanleyBoost TargetOverweight$36.00 ➝ $62.00
5/7/2020Royal Bank of CanadaBoost TargetOutperform$45.00 ➝ $53.00
5/7/2020KeyCorpBoost TargetOverweight$46.00 ➝ $52.00
5/7/2020Leerink PartnersBoost TargetOutperform$49.00 ➝ $55.00
5/7/2020Needham & Company LLCBoost TargetBuy$42.00 ➝ $55.00
5/7/2020The Goldman Sachs GroupBoost TargetSell ➝ Buy$42.00 ➝ $48.00
5/7/2020Piper SandlerBoost TargetOverweight$42.00 ➝ $55.00
4/23/2020GuggenheimInitiated CoverageBuy$46.00
4/21/2020BenchmarkInitiated CoverageBuy$55.00
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$45.00
4/13/2020Leerink PartnersInitiated CoverageOutperform$49.00
3/30/2020Needham & Company LLCReiterated RatingBuy$42.00
3/27/2020Morgan StanleyLower TargetOverweight$38.00 ➝ $36.00
3/19/2020Stifel NicolausInitiated CoverageBuy$30.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Livongo Health logo
Livongo Health, Inc. provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications. Its products include Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management, and Livongo for Behavioral Health by myStrength. The company was formerly known as EosHealth, Inc. and changed its name to Livongo Health, Inc. in 2014. Livongo Health, Inc. was incorporated in 2008 and is headquartered in Mountain View, California.
Read More

Today's Range

Now: $139.77
Low: $139.77
High: $139.77

50 Day Range

MA: $140.45
Low: $136.67
High: $148.08

52 Week Range

Now: $139.77
Low: $18.76
High: $151.05

Volume

N/A

Average Volume

3,040,795 shs

Market Capitalization

$14.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.81

Frequently Asked Questions

What sell-side analysts currently cover shares of Livongo Health?

The following equities research analysts have issued stock ratings on Livongo Health in the last year:
View the latest analyst ratings for LVGO.

What is the current price target for Livongo Health?

0 Wall Street analysts have set twelve-month price targets for Livongo Health in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Livongo Health in the next year.
View the latest price targets for LVGO.

What is the current consensus analyst rating for Livongo Health?

Livongo Health currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LVGO.

What other companies compete with Livongo Health?

Other companies that are similar to Livongo Health include Baidu, Zoom Video Communications, Pinterest, Sportradar Group and Snap. Learn More about companies similar to Livongo Health.

How do I contact Livongo Health's investor relations team?

Livongo Health's physical mailing address is 150 WEST EVELYN AVENUE SUITE 150, MOUNTAIN VIEW CA, 94041. The company's listed phone number is 866-435-5643 and its investor relations email address is [email protected]. The official website for Livongo Health is www.livongo.com. Learn More about contacing Livongo Health investor relations.